Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Chao Tian Tang

Chao Tian Tang

Institute of Mental Health, Singapore

Title: Analysing interactions: A review of treatment options for schizophrenic patients on clozapine with pulmonary tuber-culosis

Biography

Biography: Chao Tian Tang

Abstract

Statement of the Problem: Studies have observed that the incidence of pulmonary tuberculosis has been signifi cantly higher in patients with schizophrenia in countries where pulmonary tuberculosis is endemic. Patients on clozapine who are diagnosed with tuberculosis oft en present clinicians with a management dilemma. Several anti-tuberculosis medications have signifi cant interactions with clozapine with isoniazid being an inhibitor of the cytochrome P450 system, increasing the level of clozapine and rifampicin being an inducer of the cytochrome P450 system decreasing the level of clozapine. To date, clozapine is still the only evidence-based medication for treatment-refractory schizophrenia.
Orientation: A literature search was performed on several databases such as PubMed.
Findings: Patients on lower doses of clozapine could benefit from increasing the dosage of clozapine with monitoring based on serum clozapine and norclozapine levels and clinical response. Alternatives to rifampicin which have been used in case reports fluoroquinolones such as ciprofl oxacin. However, there is concern about the development of fluoroquinolones resistance in Mycobacterium tuberculosis. Streptomycin is another anti-tuberculosis medication; however, there are concerns with streptomycin given the potential ototoxicity, hepatotoxicity as well as neuropsychiatric manifestations. Conversely, increased plasma concentrations have been reported with concurrent use of clozapine and isoniazid with such a scenario requiring close monitoring of the patient’s clozapine and norclozapine level. Clozapine is associated with a dose-dependent seizure risk at a rate higher than that seen with most other antipsychotic drugs which should be closely monitored.
Conclusion: Several diff erent management strategies are available based on small anecdotal case reports. No large study has been done to determine the best treatment option for such patients. Each treatment decision should be tailor-made based on a multidisciplinary approach for the best outcome.